Core Insights - Rippling, an HR software startup, raised $450 million in Series G funding, achieving a valuation of $16.8 billion, focusing on global revenue growth over immediate profitability [1][4][5] Funding and Valuation - The funding round included participation from notable investors such as Y Combinator, Elad Gil, Sands Capital, GIC, and Goldman Sachs Growth [2] - The new valuation of $16.8 billion marks an increase from the previous valuation of $13.5 billion in early 2024 [4] Employee Equity and IPO Plans - Rippling plans to repurchase up to $200 million of equity from current and former employees through a tender offer, which may become an annual event [2][3] - The CEO stated that the company does not have immediate plans for an IPO, emphasizing the need for profitability before considering going public [4][6] Business Performance and Strategy - Rippling has surpassed $100 million in annual recurring revenue and serves over 20,000 customers with a suite of more than 20 products [5] - The company is prioritizing growth over profitability, indicating a strategic choice to expand rapidly rather than slow down for immediate profit [6] Legal Challenges - Rippling is involved in ongoing legal disputes with competitor Deel, including allegations of corporate espionage, which have raised questions about competitive practices in the tech industry [7][8]

Group 1 - The article discusses the analysis of oil and gas companies, specifically Vaalco Energy, focusing on identifying undervalued companies in the sector [1] - The analysis includes a breakdown of essential factors such as balance sheets, competitive positions, and development prospects of these companies [1] - The service, Oil & Gas Value Research, offers exclusive insights and analysis to its members, which are not available on the free site [1] Group 2 - The oil and gas industry is characterized as a boom-bust, cyclical market, requiring patience and experience for successful investment [2] - The leader of the investing group, Oil & Gas Value Research, seeks under-followed oil companies and out-of-favor midstream companies that present compelling investment opportunities [2] - The group facilitates an active chat room for investors to discuss recent information and share investment ideas [2]

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

China International Supply Chain Expo Unveils AI Zone as 100-Day Countdown Begins With 500+ Exhibitors Accessibility Statement Skip NavigationBEIJING, March 14, 2026 /PRNewswire/ -- The fourth China International Supply Chain Expo (CISCE) has entered its 100-day countdown. Themed "Connecting the World for a Shared Future," the event has evolved over three editions into an important platform for facilitating international cooperation across industrial and supply chains. Its model and value have extended well ...

Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 16.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company’s stock after selling 2,975,000 shares during the period. Amicus Therapeutics makes up about 1.5% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 20th biggest holding. Av ...

Avoro Capital Advisors LLC reduced its holdings in Alkermes plc (NASDAQ:ALKS – Free Report) by 22.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,240,000 shares of the company’s stock after selling 660,000 shares during the period. Alkermes comprises 0.9% of Avoro Capital Advisors LLC’s holdings, making the stock its 23rd biggest position. Avoro Capital Advisors LLC owned about 1.36% of Alkermes worth $67,200,000 as of its mo ...

Avoro Capital Advisors LLC lessened its holdings in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Free Report) by 51.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,000,000 shares of the company’s stock after selling 2,150,000 shares during the period. MoonLake Immunotherapeutics makes up about 0.2% of Avoro Capital Advisors LLC’s portfolio, making the stock its 27th biggest holding. Avoro Capital Advisors LLC ...

Avoro Capital Advisors LLC acquired a new position in shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,849,402 shares of the company’s stock, valued at approximately $5,414,000. Whitehawk Therapeutics comprises 0.1% of Avoro Capital Advisors LLC’s portfolio, making the stock its 29th largest holding. Avoro Capital Advisors LLC owned 6.05% of Whitehawk Therapeut ...

Avoro Capital Advisors LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 72.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,250,000 shares of the biotechnology company’s stock after selling 3,250,000 shares during the period. BioCryst Pharmaceuticals makes up 0.1% of Avoro Capital Advisors LLC’s portfolio, making the stock its 28th biggest holding. Avoro Ca ...

Avoro Capital Advisors LLC acquired a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 545,000 shares of the company’s stock, valued at approximately $4,578,000. Avoro Capital Advisors LLC owned approximately 0.40% of Tango Therapeutics at the end of the most recent reporting period. Get Tango Therapeutics alerts: Several other institutional investors a ...